March 2012
Volume 53, Issue 14
Free
ARVO Annual Meeting Abstract  |   March 2012
Factors Predictive Of Outcomes 1 Year After Ranibizumab Therapy In Japanese Patients With Polypoidal Choroidal Vasculopathy
Author Affiliations & Notes
  • Taiichi Hikichi
    Ohtsuka Eye Hospital, Sapporo, Japan
  • Makoto Higuchi
    Ohtsuka Eye Hospital, Sapporo, Japan
  • Takuro Matsushita
    Ohtsuka Eye Hospital, Sapporo, Japan
  • Shoko Kosaka
    Ohtsuka Eye Hospital, Sapporo, Japan
  • Reiko Matsushita
    Ohtsuka Eye Hospital, Sapporo, Japan
  • Kimitaka Takami
    Ohtsuka Eye Hospital, Sapporo, Japan
  • Hideo Ohtsuka
    Ohtsuka Eye Hospital, Sapporo, Japan
  • Hiroko Ariga
    Ohtsuka Eye Hospital, Sapporo, Japan
  • Footnotes
    Commercial Relationships  Taiichi Hikichi, None; Makoto Higuchi, None; Takuro Matsushita, None; Shoko Kosaka, None; Reiko Matsushita, None; Kimitaka Takami, None; Hideo Ohtsuka, None; Hiroko Ariga, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science March 2012, Vol.53, 2058. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Taiichi Hikichi, Makoto Higuchi, Takuro Matsushita, Shoko Kosaka, Reiko Matsushita, Kimitaka Takami, Hideo Ohtsuka, Hiroko Ariga; Factors Predictive Of Outcomes 1 Year After Ranibizumab Therapy In Japanese Patients With Polypoidal Choroidal Vasculopathy. Invest. Ophthalmol. Vis. Sci. 2012;53(14):2058.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : To determine the factors predictive of outcomes 1 year after ranibizumab therapy for polypoidal choroidal vasculopathy (PCV).

Methods: : One hundred fifty-five consecutive eyes of 144 Japanese patients with symptomatic PCV received one intravitreal injection of 0.5 mg ranibizumab monthly for 3 months followed by an as-needed reinjection schedule. A stepwise logistic regression model was used to estimate the independent factors predictive of better visual acuity (VA), improvement of VA, and the need for fewer injections 1 year after the first injection.

Results: : The mean (± standard deviation) number of injections during 1 year was 4.2 ± 1.3. The mean VA improved significantly from 0.63 to 0.43 logarithm of the minimum angle of resolution (P=0.001, Wilcoxon matched-pairs signed-ranks test). The VA improved and decreased more than 0.3 logMAR unit 1 year after the first injection in 54 (35%) and 14 (9%) eyes, respectively. Stepwise logistic regression analysis showed that absence of both a history of photodynamic therapy (PDT) and clusters of grape-like polypoidal lesion at baseline and improvement of polypoidal lesions 3 months after the first injection were significant and independent factors predictive of better VA 1 year after treatment; and the absence of both a history of PDT and clusters of grape-like polypoidal lesion at baseline, the presence of polypoidal PCV at baseline, worse baseline VA, and improvement of polypoidal lesions 3 months after the first injection were significant and independent factors predictive of VA improvement. No factors were predictive of fewer ranibizumab injections during 1 year after the first injection.

Conclusions: : The baseline clinical characteristics and response of polypoidal lesions to ranibizumab injections predicted favorable VA outcomes after ranibizumab therapy. These findings might help establish treatment strategies for PCV.

Keywords: age-related macular degeneration • clinical (human) or epidemiologic studies: treatment/prevention assessment/controlled clinical trials 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×